• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Solifenacin Trima
    / Trima

    Active Ingredient
    Solifenacin Succinate 5 mg, 10 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 5 mg

    partial basket chart 71844 9813


    30 X 10 mg

    partial basket chart 71846 9814

    Related information


    The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose may be increased to 10 mg solifenacin succinate once daily.
    This medicine is not intended for children and adolescents under 18 years of age.

    recommended drugs


    For symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.


    Hypersensitivity to the active ingredient or to any of the additional ingredients found in the medicine (e.g., lactose). Urinary retention. Severe gastrointestinal disorders (toxic megacolon, gastric ulcer), severe muscle weakness (myasthenia gravis), glaucoma (narrow angle) or are at risk for these conditions. Severe liver failure. Severe kidney failure that requires dialysis. Severe kidney failure or liver failure that are concomitantly being treated with medicines that affect drug elimination (e.g., ketoconazole).   

    Special Precautions

    Urine (partial obstruction), if you suffer from constipation, reduced activity of the digestive system (stomach and intestinal motility), if you suffer from an acute kidney disease, moderate liver disease, hiatus hernia or heartburn,  disturbance of the nervous system (autonomic neuropathy).
    Please refer to the license holder for further details.

    Side Effects

    Constipation, nausea, gastrointestinal effects (e.g., feeling full, abdominal pain, burping, heartburn, stomach discomfort), blurred vision.
    Please refer to the license holder for further details.

    Drug interactions

    Metoclopramide or cisapride: their efficacy may be reduced.
    Medicines that include CYP3A4 enzyme (e.g., ketoconazole, ritonavir, nelfinavir, itraconazole, verapamil, diltiazem): may prevent/delay degradation of solifenacin.
    Other anti-cholinergic preparations: may increase the effects of both medicines.
    Cholinergic preparations (e.g., pilocarpine for treating glaucoma): may reduce solifenacin efficacy.
    Bisphosphonates: may cause worsening of esophagitis.
    Please refer to the license holder for further details.

    Pregnancy and Lactation

    Please refer to the license holder for further details.


    In case of overdose, possible side effects are: headache, dry mouth, dizziness, blurred vision, drowsiness, hallucinations, convulsions, breathing difficulty, accelerated heartbeats, urinary retention, dilated pupils.
    Please refer to the license holder for further details.

    Important notes

    Lactose: Contains lactose.
    Before/after meal: May be taken with or without food.

    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel